1. Home
  2. BUUU vs IKT Comparison

BUUU vs IKT Comparison

Compare BUUU & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUUU

BUUU Group Limited Class A Ordinary Share

HOLD

Current Price

$51.06

Market Cap

305.2M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.59

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUUU
IKT
Founded
2017
2008
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
305.2M
274.9M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
BUUU
IKT
Price
$51.06
$1.59
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $5.55
AVG Volume (30 Days)
74.8K
★ 589.0K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.76
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
$347.19
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.70
$1.33
52 Week High
$52.91
$2.61

Technical Indicators

Market Signals
Indicator
BUUU
IKT
Relative Strength Index (RSI) 70.76 27.66
Support Level $13.43 N/A
Resistance Level N/A $1.74
Average True Range (ATR) 6.08 0.12
MACD 0.69 -0.02
Stochastic Oscillator 80.05 8.82

Price Performance

Historical Comparison
BUUU
IKT

About BUUU BUUU Group Limited Class A Ordinary Share

BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: